investing.comNov 12$CRBP

Mizuho cuts Corbus Pharmaceuticals stock price target on model tweaks

Mizuho reduced its price target for Corbus Pharmaceuticals (CRBP) to $23 from $24, citing model adjustments. The stock trades at $4, with targets ranging from $23 to $45. Corbus reported Q3 2026 results with higher operating expenses due to a $15M R&D payment. The company has $115.3M in cash, extending its runway into 2028. Positive Phase 1b data for CRB-913 in obesity and ongoing studies for sutantatug envedotin were noted.

Original reporting

investing.com

Published Nov 12, 2026, 11:46 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 12, 2026, 11:59 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefFinancial news

Primary signal

$CRBP

Bullish

high confidence

Mentioned

$CRBP

Relevance

8/10

AlphAI data visualization · based on investing.com

Decision brief

The 30-second read

$CRBPBullishMed

Why it matters

Analyst upgrades and positive early‑stage data provide a catalyst for short‑term price appreciation, but cash runway and burn remain concerns.

Market read

New clinical data and analyst target changes create a fresh trading signal for CRBP.

What to watch

Cash burn rate remains high; financing risk could offset trial optimism.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

The article reports analyst price target revisions and new Phase 1b trial results for Corbus Pharmaceuticals (CRBP).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CRBPBullishHigh confidence

Context

Mizuho and other analysts revised price targets for Corbus Pharmaceuticals after reporting Phase 1b obesity trial data and upcoming Phase 3 results.

Expected impact

likely upward pressure as the market prices in de‑risking from positive trial data and higher analyst targets.

Evidence & confidence

The article discloses fresh Phase 1b obesity data and multiple analyst target adjustments, which are new material for a micro‑cap biotech.

Market effects

Sector

Positive trial data may lift other oncology/obesity biotech peers.

Regional

US biotech sector could see modest gains.

Global

Limited to investors tracking early‑stage biotech pipelines.

Counterpoint

What could challenge this read

If the Phase 3 data fails to meet expectations, the recent target hikes could reverse sharply.

Key entities

company
Corbus Pharmaceuticals
NASDAQ‑listed biotech developing antibody‑drug conjugates.
analyst
Mizuho
Equity research firm that lowered its price target for CRBP.

Read at source ← All news

$CRBPMed

Corbus Q3 Loss Widens On Higher R&D Costs; CRB-701 Data Due In Q1 2027

Corbus Pharmaceuticals (CRBP) reported a wider Q3 2026 net loss of $37.75M, up from $23.34M a year earlier, due to higher R&D costs. The company's cash position is $88.34M, expected to fund operations through 2028. CRBP's CRB-701 trial is ongoing, with data expected in Q1 2027, and CRB-913 showed promising weight loss results in a Phase 1b trial.

rttnews.comNov 11

$CRBPHighAI 8/10

Oppenheimer cuts Corbus Pharmaceuticals stock price target to $40

Oppenheimer reduced its price target for Corbus Pharmaceuticals (NASDAQ:CRBP) to $40 from $48, citing recent financial results and upcoming clinical trial updates. The stock has fallen 64% over six months. The firm maintains an Outperform rating, noting potential partnering opportunities and positive clinical trial data for obesity treatment CRB-913. Corbus reported a negative free cash flow of $87 million but has a strong current ratio of 5.71.

investing.comNov 11

$CRBPMed

Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update o Dosed first patient in TEMPO-1 registrational study of sutantatug envedotin (CRB-701) in patients with 2L+ oropharyngeal cancer o Reported topline data from the CANYON-1 Phase

SEC EDGAR 8-KNov 10

$CRBPMedAI 8/10

Corbus Pharmaceuticals Launches Phase 3 Cancer Trial, Teases More Obesity Drug Data

Corbus Pharmaceuticals (CRBP) launched a Phase 3 cancer trial and shared early data on its obesity drug, CRB-913, showing 5% placebo-adjusted weight loss in a 250-patient study. The drug showed no suicidality reports and mild psychiatric side effects. Corbus plans to present more data at ObesityWeek and sees potential for combination use with GLP-1 drugs.

finance.yahoo.comNov 9

$CRBPMedAI 8/10

Corbus Pharmaceuticals updates corporate presentation, highlights CRB-701 OPSCC progress and CRB-913 obesity data

Corbus Pharmaceuticals updated its corporate presentation, reporting progress in CRB-701 for OPSCC and positive Phase 1b results for CRB-913 in obesity. The company has $118M in cash and expects interim ORR readout for CRB-701 in Q1 2027. CRB-913 showed ~5% placebo-adjusted weight loss at 12 weeks, with Phase 2 trials planned for 1H 2027.

tradingview.comOct 15

$CRBPMedAI 9/10

Corbus Obesity Pill Shows 5% Weight Loss With Clean Safety Profile in Mid-Stage Trial — BigGo Finance

Corbus Pharmaceuticals' (CRBP) obesity pill, CRB-913, achieved 5% weight loss in a 12-week mid-stage trial with no serious psychiatric side effects, positioning it for Phase 2 testing. The drug showed dose-dependent weight loss and a favorable safety profile compared to earlier CB1 inverse agonists. Corbus plans to discuss Phase 2 trial plans with the FDA. Shares have risen 342% year-to-date.

finance.biggo.comSep 15